US 11,964,983 B2
Selective CDK4/6 inhibitor cancer therapeutics
Michael P. Lisanti, Didsbury Village Greater Manchester (GB); Federica Sotgia, Didsbury Village Greater Manchester (GB); and Jussi Kangasmetsa, Cambridge (GB)
Assigned to LUNELLA BIOTECH, INC., Ontario (CA)
Appl. No. 18/008,636
Filed by LUNELLA BIOTECH, INC., Ottawa (CA)
PCT Filed Jun. 10, 2021, PCT No. PCT/IB2021/055124
§ 371(c)(1), (2) Date Dec. 6, 2022,
PCT Pub. No. WO2021/250614, PCT Pub. Date Dec. 16, 2021.
Claims priority of provisional application 63/037,898, filed on Jun. 11, 2020.
Prior Publication US 2023/0227461 A1, Jul. 20, 2023
Int. Cl. C07D 487/14 (2006.01); C07D 487/20 (2006.01)
CPC C07D 487/14 (2013.01) [C07D 487/20 (2013.01)] 5 Claims
 
1. A compound comprising the general formula

OG Complex Work Unit Chemistry
in which:
‘m’ is an integer from 0-4, ‘n’ is an integer from 13 to 22, and R1 is selected from the group consisting of hydrogen, C1-C8-alkyl, substituted C1-C8-alkyl, C3-C8-cycloalkyl, substituted C3-C8-cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.